University Library

MINERVA ACCESS

A gateway to Melbourne's research publications

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Deb, S;Gorringe, KL;Pang, JMB;Byrne, DJ;Takano, EA;Investigators, CF;Dobrovic, A;Fox, SB

Title:
BRCA2 carriers with male breast cancer show elevated tumour methylation

Date:
2017-09-11

Citation:
Deb, S., Gorringe, K. L., Pang, J. M. B., Byrne, D. J., Takano, E. A., Investigators, C. F., Dobrovic, A. & Fox, S. B. (2017). BRCA2 carriers with male breast cancer show elevated tumour methylation. BMC Cancer, 17 (1), https://doi.org/10.1186/s12885-017-3632-7.

Persistent Link:
https://hdl.handle.net/11343/255088

License:
CC BY

Deb et al. BMC Cancer (2017) 17:641
DOI 10.1186/s12885-017-3632-7

BMC Cancer

RESEARCH ARTICLE Open Access

BRCA2 carriers with male breast cancer show elevated tumour methylation

Siddhartha Deb[1,2], Kylie L. Gorringe[2,3,4], Jia-Min B. Pang[1], David J. Byrne[1], Elena A. Takano[1], kConFab Investigators[5], Alexander Dobrovic[1,4,6,7] and Stephen B. Fox[1,2,4,7*]

Abstract

Background: Male breast cancer (MBC) represents a poorly characterised group of tumours, the management of which is largely based on practices established for female breast cancer. However, recent studies demonstrate biological and molecular differences likely to impact on tumour behaviour and therefore patient outcome. The aim of this study was to investigate methylation of a panel of commonly methylated breast cancer genes in familial MBCs.

Methods: 60 tumours from 3 *BRCA1* and 25 *BRCA2* male mutation carriers and 32 males from BRCAX families were assessed for promoter methylation by methylation-sensitive high resolution melting in a panel of 10 genes (*RASSF1A*, *TWIST1*, *APC*, *WIF1*, *MAL*, *RARβ*, *CDH1*, *RUNX3*, *FOXC1* and *GSTP1*). An average methylation index (AMI) was calculated for each case comprising the average of the methylation of the 10 genes tested as an indicator of overall tumour promoter region methylation. Promoter hypermethylation and AMI were correlated with *BRCA* carrier mutation status and clinicopathological parameters including tumour stage, grade, histological subtype and disease specific survival.

Results: Tumours arising in *BRCA2* mutation carriers showed significantly higher methylation of candidate genes, than those arising in non-*BRCA2* familial MBCs (average AMI 23.6 vs 16.6, $p = 0.01$, 45% of genes hypermethylated vs 34%, $p < 0.01$). *RARβ* methylation and AMI-high status were significantly associated with tumour size ($p = 0.01$ and $p = 0.02$ respectively), *RUNX3* methylation with invasive carcinoma of no special type (94% vs 69%, $p = 0.046$) and *RASSF1A* methylation with coexistence of high grade ductal carcinoma in situ (33% vs 6%, $p = 0.02$). Cluster analysis showed MBCs arising in *BRCA2* mutation carriers were characterised by *RASSF1A, WIF1*, *RARβ* and *GTSP1* methylation ($p = 0.02$) whereas methylation in BRCAX tumours showed no clear clustering to particular genes. *TWIST1* methylation ($p = 0.001$) and AMI ($p = 0.01$) were prognostic for disease specific survival.

Conclusions: Increased methylation defines a subset of familial MBC and with AMI may be a useful prognostic marker. Methylation might be predictive of response to novel therapeutics that are currently under investigation in other cancer types.

Keywords: Male breast cancer, Familial breast cancer, Methylation, BRCA1, BRCA2, Promoter methylation

Background

Male breast cancer (MBC) is a poorly studied disease. Indeed, MBC accounts for ~1% of all breast cancers but it contributes to a higher proportion of breast cancer-related deaths [1, 2]. As a significant proportion of MBCs arise within breast/ovarian families, the majority of MBC research has focused on cancer predisposition. However, differences in genotype-phenotype between female and male breast cancers suggest that MBCs have alternate and novel drivers [3–5].

It is now well recognised that aberrant modification of gene expression by promoter methylation is often pathogenic and not an inconsequential contributor to oncogenesis: indeed epigenomic changes are often more commonly observed than gene mutations and chromosomal instability in many cancers [6]. In cancer, aberrant methylation is frequently seen within CpG islands in promoter regions often resulting in transcriptional silencing [7] often occurring early in cancer development.

* Correspondence: stephen.fox@petermac.org
[1]Molecular Pathology Research and Development Laboratory, Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
[2]Sir Peter MacCallum Department of Oncology, The University of Melbourne, Vic, Parkville 3010, Australia
Full list of author information is available at the end of the article

BioMed Central

© The Author(s). 2017 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

From a clinical perspective, gene methylation may not only contribute to the biological understanding of cancer subsets, but may also be utilised in screening, staging and monitoring of disease activity, as methylation is stable in formalin-fixed paraffin-embedded pathology material and in plasma. Methylated genes may also be attractive treatment targets in MBC using therapies in trials in other tumour types [8].

To date only three MBC studies, composed of a total of 182 male breast cancers, have evaluated methylation in MBCs, which showed that promoter gene methylation in MBC, as compared to normal male breast tissue, is a common event and associated with a more aggressive phenotype [9–11]. However, the methodologies used are prone to give false positive results and/or are non-quantitative. To address the paucity of data we have performed methylation profiling in a well-characterised series of MBC. Our aims were to 1) determine the frequency and level of methylation of important breast cancer genes in a large cohort of familial MBCs, 2) identify clinicopathological associations, including patient outcome, that may define a biological effect of gene methylation and 3) identify and characterise potential molecular subgroups defined by their methylation patterns with clinicopathological correlation.

Methods

Patient samples

Primary male breast cancers examined in this study were obtained from the Kathleen Cunningham Foundation Consortium (kConFab) breast/ovarian familial cancer repository (Table 1). Cases are accepted into the registry based on a strong family history of breast and ovarian cancer with criteria for admission to the kConFab study as outlined previously [12], with all participants providing informed consent to participate in research studies. Patients were from Australia and New Zealand and diagnosed between 1980 and 2009.

The flow of patients through the study was according to the REMARK criteria outlined in Additional file 1 [13]. Of the 118 cases within the kConFab registry, 58 cases were excluded due to unavailability of tissue. Sixty cases had sufficient material at an appropriate DNA concentration for methylation testing as outlined below. These cases belonged to three groups: 3 MBCs that arose in *BRCA1* mutation carriers, 25 that arose in *BRCA2* mutation carriers and 32 that occurred in males from BRCAX families (i.e. where an underlying germline mutation had not been identified).

Clinical parameters, including disease specific survival (DSS) were obtained from referring clinical centres, kConFab questionnaires and state death registries [14, 15]. Information on pedigrees, mutational status and testing were available from the kConFab central registry.

Table 1 Clinicopathological description of male breast cancers in this study

Feature		
Age (years)	Median = 62.5	Range: 30–85
Mutation carrier status		
BRCA1	3	5.0%
BRCA2	25	41.7%
BRCAX	32	53.3%
Size (mm)	Median = 17	Range: 2–50
Histological subtype		
Invasive carcinoma - no special type (IC-NST)	46	76.7%
Invasive papillary carcinoma	8	13.3%
IC-NST with areas of micropapillary	4	6.7%
Invasive lobular carcinoma	2	3.3%
Grade		
1	2	3.3%
2	30	50.0%
3	28	46.7%
DCIS		
Present	41	68.3%
Absent	15	25.0%
Unknown	4	6.7%
Nodal Status		
N0	28	46.7%
N1	20	33.3%
Nx	12	20.0%
Paget's Disease		
Present	8	13.3%
Absent	44	73.3%
Unknown	8	13.3%
ER status (Allred score)		
Negative (0–4/8)	2	3.3%
Positive (5–8/8)	58	96.7%
PgR status (allred score)		
Negative (0–4/8)	8	13.3%
Positive (5–8/8)	52	86.7%
HER2 (SISH)		
Amplified	5	8.3%
Non-amplified	55	91.7%
Phenotype		
Luminal	54	90.0%
HER2	5	8.3%
Basal	1	1.7%

Histological classification was based on criteria set by the World Health Organisation 2012 [16] and all slides and pathological records from all cases were reviewed centrally. Immunohistochemistry for estrogen receptor (ERα), progesterone receptor (PgR), basal markers (cytokeratin 5 (CK5), EGFR) and HER2 silver in-situ hybridisation (SISH) was performed as previously reported [4]. Stratification of intrinsic phenotypes was based on Nielsen et al. [17], and placed into luminal (ERα/PgR positive, HER2 negative, CK5 and/or EGFR negative), basal (ER α/PgR and HER2 negative; CK5 and/or EGFR positive), HER2 (HER2 positive) and null/negative (HER2, ERα, PgR, CK5 and EGFR negative) phenotypes. Permission to access the kConFab samples and data was granted by the kConFab Executive Committee (Project #115/07–17). This work was carried out with approval from the Peter MacCallum Cancer Centre Ethics Committee (Project No: 11/61).

Germline *BRCA1/2* testing

Mutation testing for *BRCA1* and *BRCA2* mutations was performed as previously reported [18, 19]. Once the family mutation had been identified, all pathogenic (including splice site) variants of *BRCA1* and *BRCA2* were genotyped by kConFab in all available family members' DNA.

DNA extraction

Genomic DNA was extracted from formalin-fixed, paraffin embedded (FFPE) samples. A 3 μM haematoxylin and eosin (H&E) stained slide was cut from FFPE blocks and stained to identify for tumour enriched areas showing >80% tumour purity. From the relevant area on the FFPE block, one to two 2 mm punch biopsy cores were taken. The cores were then dewaxed and hydrated through a decreasing alcohol series. Genomic DNA was then extracted using the DNeasy Tissue kit (Qiagen, Hilden, Germany) following proteinase K digestion at 56 °C for 3 days.

Bisulfite modification

Genomic DNA (600 ng) was bisulfite modified using the MethylEasy™ Xceed kit (Genetic Signatures, North Ryde, Australia) according to the manufacturer's instructions. The bisulfite modified DNA was eluted into 50 μL of EB buffer. CpGenome™ Universal Methylated DNA (Chemicon/Millipore, Billerica, MA) and whole-genome amplified DNA [20] were used as the fully methylated and unmethylated controls, respectively. DNA methylation standards (10, 25 and 50%) were made by mixing the fully methylated control with the unmethylated DNA control.

Methylation-sensitive high resolution melting (MS-HRM)

Methylation screening was performed using MS-HRM to quantitate methylation in bisulfite-modified samples according to the sequence-dependent thermostability in which the level and presence of homogenous and heterogeneous methylation can be detected [21, 22]. MS-HRM primers were specifically designed to generate short amplicons enabling use in formalin-fixed paraffin embedded (FFPE) samples and are summarised in Additional file 2.

PCR amplification and HRM analysis were performed on the Rotor-Gene 6000 (Corbett, Sydney). Samples were run in duplicate. Conditions for each gene are described in Additional file 2. The reaction was performed using a final volume of 20 μL and the mixture consisted of 1 × PCR buffer (Qiagen, Hilden, Germany), 2.5–4.0 mmol/L of $MgCl_2$, 200 μmol/L of each dNTP, forward and reverse primers, 5 μmol/L of SYTO9 intercalating dye (Invitrogen, Carlsbad, CA), 0.5 U of HotStarTaq DNA polymerase (Qiagen, Hilden, Germany) and 10 ng of bisulfite modified DNA. The methylation level of each DNA sample was determined visually by comparing it against the standard curves. Heterogeneous DNA methylation was defined by melting profiles that did not directly conform to any of the methylation controls due to the formation of heteroduplexes between closely but not identically related single complementary DNA strands. Complexes that complete melting slightly after the unmethylated controls were indicative of low levels of DNA methylation. In contrast, complexes with a late melting profile typically contained more heavily methylated epialleles (Fig. 1).

Methylation scoring

A cut-off of 10% methylation was used to primarily exclude low level methylation of uncertain biological significance. The remaining samples were further grouped into moderate methylation (10–50% fully methylated, or moderate heterogenous methylation) and high methylation (>50% fully methylated, or high-level heterogenous methylation) (Fig. 1). Positive methylation (hypermethylation) for each gene was thus considered when duplicate samples showed >10% or moderate to high heterogeneous methylation The samples were also given a percentage methylation for each gene by comparing the methylation to the curves of the standard, which was then averaged across all the genes to give a average methylation index (AMI) scored between 0 and 100% for each tumour sample [23]. The AMI measurement is based on the cumulative methylation index [24], which is the sum of the percentages of methylation of the individual genes, but corrects for the number of genes tested. Using the AMI scores, groups were dichotomised into low and high based on the median AMI as a cut-off point. This analysis does not make assumptions as to the effect of any particular level of methylation.

Cluster analysis

Unsupervised complete linkage clustering was performed with Euclidean metric distance. Unsupervised hierarchical



Fig. 1 **a** Schematic representation of an unmethylated sample, homogenously methylated sample and heterogeneously methylated sample (circles represent CpG islands with white indicating unmethylated and black indicating methylated sites), **b** quantitation of homogenous methylation (*RARβ*), **c** quantitation of heterogeneous methylation (*RUNX3*)

cluster analysis of methylation at each gene was used to detect possible distinct molecular signatures. Analysis was performed using Cluster and Tree View software written by Michael Eisen (Stanford University) as previously published [25–27].

Statistical analysis

Comparison of groups was made with using Mann-Whitney U for non-parametric continuous distributions and Fisher's exact test for threshold data. Kaplan-Meier survival curves were plotted using breast cancer related death as the endpoint and compared using a log rank test. Pearson's correlation coefficient was measured for the cluster analysis. Analysis was performed with GraphPad Prism 5 software (GraphPad Prism version 5.04 for Windows, GraphPad Software, La Jolla California USA). A two-tailed *P*-value test was used in all analyses and a *p*-value or less than 0.05 was considered statistically significant.

Results

Methylation analysis of MBCs finds associations with genotype and clinico-pathological characteristics

We performed methylation analysis on 60 MBC (25 *BRCA2*, 3 *BRCA1* and 32 BRCAX), whose clinical and pathological features are summarised in Table 1. The features of these cases are consistent with familial male breast cancers in the literature [28], primarily being invasive carcinomas of no special type (76%), ER and PR positive (97% and 87% respectively) and HER2 unamplified (92%). Fifty four (90%), five (8%) and one (2%) tumour(s) were luminal, HER2 and basal phenotypes respectively.

We selected 10 genes for analysis based on their frequency of methylation and/or association with prognosis in previous studies of breast cancer, as follows. Methylation of *GSTP1 and RASSF1A* is common in MBC [10, 11]. Methylation of *WIF1*, *TWIST*, *FOXC1*, *APC*, *RARb* and *MAL* have also been associated with patient outcome in FBC [29–33]. *CDH1*, *RARB* and *RUNX3* are frequently methylated in 22–72% [34–36], 20–45% [35, 37, 38] and 50–90% of FBC respectively [39, 40].

GSTP1 was the most commonly methylated gene (82%), followed by *RASSF1A* (68%), with both showing a pattern of predominantly high level methylation (Table 2). Other genes were more varied: *RARβ*, *APC* and *RUNX3* had moderate levels of methylation, while heterogeneous methylation was observed in *TWIST1*, *MAL* and *WIF1*, with a mix of moderate and high heterogeneous methylation. Only low level methylation was observed in *CDH1* with no cases showing hypermethylation. There were no statistically significant associations of specific gene methylation with patient genotype, however, there were trends

Table 2 Percentage of cases with hypermethylation

	GSTP1	*RASSF1A*	*MAL*	*TWIST*	*RUNX3*	*RARβ*	*APC*	*FOXC1*	*CDH1*	*WIF1*	TOTAL HYPERMETHYLATED GENES	AMI (mean)
BRCA1 ($n = 3$)	2 (66%)	1 (33%)	1 (33%)	0	1 (33%)	1 (33%)	1 (33%)	1 (33%)	0	1 (33%)	9 (30%)	13.4
BRCA2 ($n = 25$)	22 (88%)	20 (80%)	14 (56%)	13 (52%)	8 (32%)	11 (44%)	8 (32%)	6 (24%)	0	11 (44%)	113 (45%)	23.6
BRCAX ($n = 32$)	25 (78%)	20 (63%)	12 (38%)	9 (28%)	9 (28%)	6 (19%)	7 (22%)	8 (25%)	0	14 (56%)	110 (34%)	17.0
All ($n = 60$)	49 (82%)	41 (68%)	27 (45%)	22 (37%)	18 (30%)	18 (30%)	16 (27%)	15 (25%)	0	26 (43%)	232 (39%)	14.0
				$p = 0.06$		$p = 0.08$					$P < 0.01$	$p = 0.01$

for higher methylation frequency of *RARβ* (44% vs 20%, $p = 0.08$) and *TWIST1* (52% vs 26%, $p = 0.06$) in *BRCA2* carriers. Overall, the *BRCA2* group also showed a higher rate of gene hypermethylation (45% vs 34%, $p < 0.01$) in our target suppressor gene panel than the other groups.

We examined the association of specific gene methylation with patient and tumour characteristics (Table 3). *APC* hypermethylation was significantly associated with older age (69.1 years vs 60.4 years, $p = 0.01$, Table 2) whereas *MAL* hypermethylation was significantly inversely associated with age (59.1 years vs 65.7 years, $p = 0.04$). Significantly larger tumour size was noted for cases with *RARβ* hypermethylation (median 22.3 mm vs 16.5 mm; $p = 0.01$). *RARβ* hypermethylation was also associated with a higher percentage of Paget's disease (31% vs 8%, $p = 0.04$). *RUNX3* hypermethylation was associated with increased frequency of IC-NST histological type (94% vs 69%, $p = 0.046$) and *RASSF1A* hypermethylation associated with the coexistence of high grade DCIS (33% vs 6% ($p = 0.02$).

High overall levels of methylation have been associated with aggressive tumour features such as mitotic count, grade and poor patient outcome in MBC [10] and FBC [30, 41]. Therefore, we calculated a measure of overall methylation for each sample, the AMI. There was a significant increase in AMI in *BRCA2* mutation carriers compared with other MBCs (23.6 vs 16.6, $p = 0.01$, Fig. 2). In addition, the AMI was positively correlated with tumour size (median 22.4 mm vs 15.4 mm, $p = 0.02$).

Cluster analysis identifies subgroups of MBC

In order to evaluate whether methylation profiles could discover novel subgroups in MBC, as has been seen for FBC [42, 43] and colorectal cancer [44], we performed an unsupervised clustering analysis. Four main clusters with at least 7 samples in each group were identified (Fig. 3). MBCs arising in *BRCA2* carriers showed a significantly greater frequency (6/7 vs 19/53, $p = 0.02$) of Cluster 3 membership (characterised by *RASSF1A, WIF1, GSTP1* and *RARβ* methylation). No other clinicopathological association or prognostic differences were seen between the clusters.

Analysis of methylation patterns within the *BRCA2* subgroup of tumours showed two clusters with correlation coefficients >0.8) (Additional file 3). Cluster A contained 12 tumours and was characterised by high *GSTP1* methylation and *MAL* methylation and relatively lower *RASSF1A* methylation. Cluster B contained 8 tumours and showed primarily high *RASSF1A* methylation. Cluster A tumours showed an earlier age at diagnosis than

Table 3 Correlation of hypermethylation with clinicopathological variables (associations approaching significance, $p < 0.05$ in bold)

	GSTP1		*RASSF1A*		*MAL*		*RUNX3*		*RARβ*		*APC*		*FOXC1*		AMI (median)	
Hypermethylation	+	-	+	-	+	-	+	-	+	-	+	-	+	-	>	<
Age (years)					59.1	65.7			67.2	60.9	69.1	60.4				
p-value						**0.04**				0.07		**0.01**				
Tumour size (mm)									22.3	16.5	21.4	17.1			20.8	15.8
p-value										**0.01**		0.08				**0.02**
IC-NST Histology							94%	69%								
p-value								**0.046**								
Grade 3	51%	18%														
p-value		0.09														
Paget's Disease									31%	8%						
p-value										**0.04**						
DCIS present			33%	6%												
p-value				**0.02**												
Lymphovascular invasion	49%	18%									20%	51%	53%	40%		
p-value		0.09										0.07		0.09		
Perineural invasion									63%	36%						
p-value										0.07						
Node positive			52%	24%					62%	34%						
p-value				0.08						0.07						
HER2 positive															13%	0
p-value																0.11



Fig. 2 Average methylation index (AMI) for samples stratified by BRCA status (Central bar – median, error bars = 1 standard deviation)

other *BRCA2* tumours. Other variables did not align to one or the other cluster. Analysis of BRCAX tumours by cluster analysis showed only very small clusters of 6 or less patients with a correlation coefficient above 0.8 (Additional file 3).

A high average methylation index and *TWIST1* hypermethylation associated with worse disease specific survival

Both a high AMI (HR:3.3, 95% CI:1.3–7.0, p = 0.01) and hypermethylation of *TWIST1* (HR:3.7, 95% CI:2.0–12.9, p = 0.001) were adverse features for disease specific survival (Fig. 4) with *TWIST1* methylation (HR:4.7, 95% CI:2.0–27.5, p = 0.01) also being associated with a significantly shorter survival in the *BRCA2* MBC sub-group. Because *BRCA2* tumours have higher methylation overall and also worse survival than other MBC cohorts [45, 46], we also evaluated survival within the *BRCA2* carriers, and observed a trend towards worse outcome with higher AMI in this sub-group (HR:3.3, 95% CI: 0.8–9.7, p = 0.1). Hypermethylation of *FOXC1* (HR:2.3, 95% CI:0.99–8.1, p = 0.053) showed a strong trend towards worse DSS; hypermethylation of other genes showed no prognostic information. No significant association with progression-free survival was detected for any gene or AMI. Multivariate analysis was not performed due to inadequate numbers of cases.

Discussion

Aberrant methylation of promoter regions of tumour suppressor genes has been shown to be a frequent mechanism of gene silencing in most cancers, including breast cancers [47–49]. In many instances, this is observed in adjacent normal tissues or in pre-invasive lesions [50]. Perhaps best seen in colorectal cancer [51],



	Cluster 1	Cluster 2	Cluster 3	Cluster 4
Methylated genes	GTSP1, MAL > RASSF1A, WIF1	GTSP1	RASSF1A > WIF1, RARB, GTSP1	TWIST1 > RASSF1A
Correlation	0.49	0.45	0.55	0.37
BRCA genetype				
BRCA1	1	1	0	0
BRCA2	7	5	6*	4
BRCAX	10	13	1	4

* p = 0.02

Fig. 3 Unsupervised cluster analysis of methylation amongst male breast cancers (gradation is seen in the shading between white (no methylation) and red (high methylation))



Fig. 4 Disease specific survival of average methylation index (AMI), *TWIST1* and *FOXC1* in all male breast cancers and within the *BRCA2* and BRCAX subgroups

subsets may demonstrate methylation patterns with clinical relevance.

We have used methylation sensitive high-resolution melting analysis of methylation as it has been demonstrated to be highly sensitive, robust and effective in evaluating FFPE tissue, able to differentiate and semi-quantitate homogenous and heterogeneous methylation [22, 52]. This current comparative study is the largest to examine methylation using a robust technology of well characterised and acknowledged tumour suppressor genes shown to be methylated and important in the pathogenesis FBC, in a clinically well annotated cohort of familial male breast cancers with known mutation status. We have identified frequent promoter hypermethylation (≥30%) in *GSTP1*, *RASSF1A*, *MAL*, *TWIST*, *RUNX3*, and *RARβ*, and identified significant associations with clinico-pathological features in five of the genes assayed. One caveat to some of these associations is that the small sample size and their level of statistical significance close to the $p < 0.05$ threshold may mean that false positive results are included due to the multiple tests performed.

Currently there are only three published methylation studies in a total of 182 male breast cancers. Of the genes we investigated only methylation at *GSTP1*, *RARβ*

and *RASSF1A* have been individually assessed, The largest study by Kornegoor et al. [10] examined candidate methylation of 25 genes in 108 MBCs by methylation specific multiplex ligation dependent probe amplification (MS-MLPA), detecting methylation in *RARβ* (5%) and *GSTP1* (44%), somewhat lower than our results. This study did not segregate MBC into sporadic and familial groups, which have been shown to contain distinct geno-phenotypic characteristics and may explain the difference in frequency observed. The second study by Pinto et al. [11] evaluated *RASSF1A* (76%) and *RARβ* (8%) in 27 familial MBCs using quantitative methyl-specific PCR. The lower frequency of *RARβ* hypermethylation observed may be explained by the lower proportion of *BRCA2* cases included (3/27 compared to 25/60 in our cohort). Consistent with this possibility we observed a trend for *RARβ* methylation to be higher in *BRCA2* cases. Finally, Johanssen et al. [9] performed genome-wide methylation profiling in 47 MBCs, and identified two clusters of cases; unfortunately germline mutation status was only available for 8 cases.

One of the most striking findings in this study is the high frequency of *GSTP1* methylation (82%), which has not been noted before. *GSTP1* encodes for glutathionine S transferase P [53] and may be a critical gene in the development of familial MBCs. Very high levels of *GSTP1* methylation are also seen in prostate cancer, which is another male cancer that can be associated with *BRCA2* mutation [54, 55]. We noted high levels of *GSTP1* methylation in both *BRCA2* (88%) and BRCAX tumours (78%), well above that noted by Kornegoor et al. (44%) and that reported in FBCs (generally <60%) [56, 57]. The reason for this result is unlikely to be assay related, as using the same methodology we have shown similar levels of methylation in FBC to that reported in the literature. There are two other possibilities. Firstly, *GSTP1* methylation may be ERβ mediated as studies of prostate cancer lines show that the ERβ/eNOS complex causes *GSTP1* repression by local chromatin remodelling following recruitment to estrogen responsive elements [58]. Secondly, *GSTP1* functions as a caretaker gene [53, 58, 59] with its loss resulting in increased oxidative DNA damage and mutagenesis, thus, in *BRCA2* deficient cancers already sensitive to oxidative stress [60], any loss of *GSTP1* may have a more pronounced effect and be integral in tumour development.

We also noted overall methylation differences between the *BRCA2* and BRCAX subgroups further supporting previous studies showing a possible *BRCA2* MBC subset. In female *BRCA2* carriers, promoter hypermethylation has also been shown to be elevated compared to non-familial and *BRCA1* carriers [49, 61]. Methylation profiling of FBC was able to discriminate *BRCA1*, *BRCA2* and two subsets of BRCAX tumours [61]. This study is the first to report on methylation of male breast cancers arising in *BRCA1* mutation carriers. These tumours are rare, and while we only have three cases within our cohort, this is a novel group. We were unable to see a significant correlation between gene hypermethylation and *BRCA1* status but did observe the lowest levels of methylation of all the groups, mirroring the findings seen in *BRCA1* associated female breast cancer. Further investigation of this rare subgroup is warranted.

This high level of methylation could potentially be used for screening in *BRCA2* male carriers as methylation is not seen in normal tissues, serum or plasma of normal individuals but can be detected in blood. *GSTP1* may be the prime candidate as studies evaluating its use as a biomarker for prostate cancer are well advanced.

To aid the above possible screening strategies we have developed an index of methylation (AMI) to investigate the quanta of methylation. We observed that AMI correlated with larger tumour size and shorter disease specific survival suggesting that either a stochastic accumulation of methylation and/or a methylator phenotype leads to a more aggressive tumour, as observed in the study of Kornegoor et al. [10]. Similarly, Johansson et al. [9] found that a highly methylated MBC subgroup was more proliferative and showed a trend towards worse patient outcome. In sporadic FBC conflicting results regarding methylation and survival have been found, with higher methylation subgroups showing either improved prognosis [43] or poor overall survival [62]. These differences are perhaps explained by the influence of the intrinsic subtypes, which show distinct methylation patterns and patient outcome [49]. The association between multigene hypermethylation and outcome in familial FBC does not appear to have been evaluated. Notably, in our cohort a high AMI maintained a trend towards prognostic significance in *BRCA2* tumours further suggesting that as above, methylation has particular biological importance in this subset of tumours.

Conclusions

We have shown that tumour promoter methylation within our target suppressor gene panel is commonly observed in familial and particularly *BRCA2* male breast cancers suggesting aberrant hypermethylation may be a significant driver in MBCs carrying prognostic information. In addition, the presence of specific methylation patterns particular to MBC subtypes such as *BRCA2* carriers further supports emerging evidence suggesting the presence of unique and distinct MBC subsets that differ from other MBC subgroups and from FBC.

Additional files

Additional file 1: Table S1. REMARK patient flow through study (XLSX 34 kb)

Additional file 2: Table S2. Methylation specific high resolution melting condition and primers (XLSX 36 kb)

Additional file 3: Figure S1. a) BRCA2 subgroup cluster analysis, b) BRCAX subgroup cluster analysis, c) Numbers and sizes of clusters within BRCA2 and BRCAX subgroups using various correlation coefficient cut-offs (listed on the x-axis), d) age of diagnosis of patient within Cluster A, B and other BRCA2 tumours (DOCX 234 kb)

Abbreviations
AMI: Average methylation index; CK5: Cytokeratin 5; DCIS: Ductal carcinoma in situ; DSS: Disease specific survival; ERα: Estrogen receptor; FBC: Female breast cancer; FFPE: Formalin-fixed, paraffin embedded; H&E: Haematoxylin and eosin; IC-NST: Invasive carcinomas of no special type; kConFab: Kathleen Cuningham Foundation Consortium; MBC: Male breast cancer; MS-HRM: Methylation-sensitive high resolution melting; MS-MLPA: Methylation-specific multiplex ligation dependent probe amplification; PgR: Progesterone receptor; QMSP: Quantitative methyl-specific PCR

Acknowledgements
We wish to thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow up Study (National Breast Cancer Foundation and Cancer Australia #628333) for their contributions to this resource, and the many families who contribute to kConFab.

Funding
kConFab is supported by grants from the National Breast Cancer Foundation, the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. Siddhartha Deb received a postgraduate scholarship from the NHMRC. Funding from the National Breast Cancer Foundation (AD), Victorian Cancer Agency (KG), the Cancer Council of Victoria (AD) and Cancer Australia also supported this study.

Authors' contributions
SD – Project conceptualization, DNA extraction and performing methylation assays, data analysis, preparation of manuscript, KLG – data interpretation, preparation of manuscript, JMP - Preparation of standards and performing methylation assays, ET – Performing methylation assay, kConFab Investigators – preparation of clinical data, AD – Project and assay design, technical supervision, manuscript review, SBF – Project conceptualization, manuscript preparation and review. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This work was carried out with approval from the Peter MacCallum Cancer Centre Ethics Committee (Project No: 11/61). All patients provided written informed consent for the use of their tissue and data.

Consent for publication
not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
[1]Molecular Pathology Research and Development Laboratory, Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. [2]Sir Peter MacCallum Department of Oncology, The University of Melbourne, Vic, Parkville 3010, Australia. [3]Cancer Genomics Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. [4]Department of Pathology, University of Melbourne, Parkville, VIC 3012, Australia. [5]Kathleen Cuningham Foundation Consortium for research into Familial Breast Cancer, Peter MacCallum Cancer Centre, Melbourne 3000, Australia. [6]Translational Genomics and Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia. [7]School of Cancer Medicine, La Trobe University, Bundoora, VIC 3084, Australia.

Received: 8 March 2017 Accepted: 28 August 2017
Published online: 11 September 2017

References
1. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28(12):2114–22.
2. Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomark Prev. 2005;14(1):20–6.
3. Deb S, Do H, Byrne D, Jene N, kConFab I, Dobrovic A, Fox SB. PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer. Breast Cancer Res. 2013;15(4):R69.
4. Deb S, Jene N, Fox SB. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC Cancer. 2012;12:510.
5. Deb S, Johansson I, Byrne D, Nilsson C, Investigators K, Constable L, Fjallskog ML, Dobrovic A, Hedenfalk I, Fox SB. nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer. Mod Pathol. 2014;27(9):1223–30.
6. Heichman KA, Warren JD. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med. 2012;50(10):1707–21.
7. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042–54.
8. Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007;13(6):1634–7.
9. Johansson I, Lauss M, Holm K, Staaf J, Nilsson C, Fjallskog ML, Ringner M, Hedenfalk I. Genome methylation patterns in male breast cancer - identification of an epitype with hypermethylation of polycomb target genes. Mol Oncol. 2015;9(8):1565–79.
10. Kornegoor R, Moelans CB, Verschuur-Maes AH, Hogenes M, de Bruin PC, Oudejans JJ, van Diest PJ. Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Res. 2012;14(4):R101.
11. Pinto R, Pilato B, Ottini L, Lambo R, Simone G, Paradiso A, Tommasi S. Different methylation and microRNA expression pattern in male and female familial breast cancer. J Cell Physiol. 2013;228(6):1264–9.
12. Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, Evans GM, Fereday S, Haan E, Gattas M, et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res. 2006;8(1):R12.
13. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23(36):9067–72.
14. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet. 2004;36(5):497–501.
15. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994;7(4):536–40.
16. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJE: WHO classification of Tumours of the breast: IARC: Lyon 2012.
17. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367–74.
18. Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res. 2003;63(7):1449–53.
19. Lum A, Le Marchand L. A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer Epidemiol Biomark Prev. 1998;7(8):719–24.
20. Kristensen LS, Mikeska T, Krypuy M, Dobrovic A. Sensitive melting analysis after real time- methylation specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res. 2008;36(7):e42.

21. Mikeska T, Candiloro IL, Dobrovic A. The implications of heterogeneous DNA methylation for the accurate quantification of methylation. Epigenomics. 2010;2(4):561–73.
22. Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007;35(6):e41.
23. Pang JM, Deb S, Takano EA, Byrne DJ, Jene N, Boulghourjian A, Holliday A, Millar E, Lee CS, O'Toole SA, et al. Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features. Breast Cancer Res. 2014;16(5):423.
24. Fackler MJ, Malone K, Zhang Z, Schilling E, Garrett-Mayer E, Swift-Scanlan T, Lange J, Nayar R, Davidson NE, Khan SA, et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res. 2006;12(11 Pt 1):3306–10.
25. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95(25):14863–8.
26. Makretsov NA, Huntsman DG, Nielsen TO, Yorida E, Peacock M, Cheang MC, Dunn SE, Hayes M, van de Rijn M, Bajdik C, et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res. 2004;10(18 Pt 1):6143–51.
27. van de Rijn M, Gilks CB. Applications of microarrays to histopathology. Histopathology. 2004;44(2):97–108.
28. Deb S, Lakhani SR, Ottini L, Fox SB. The cancer genetics and pathology of male breast cancer. Histopathology. 2016;68(1):110–8.
29. Cheol Kim D, Thorat MA, Lee MR, Cho SH, Vasiljevic N, Scibior-Bentkowska D, Wu K, Ahmad AS, Duffy S, Cuzick JM, et al. Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes. Cancer Biomark. 2012;11(2–3):75–88.
30. Cho YH, Shen J, Gammon MD, Zhang YJ, Wang Q, Gonzalez K, Xu X, Bradshaw PT, Teitelbaum SL, Garbowski G, et al. Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat. 2012;131(1):197–205.
31. Dejeux E, Ronneberg JA, Solvang H, Bukholm I, Geisler S, Aas T, Gut IG, Borresen-Dale AL, Lonning PE, Kristensen VN, et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer. 2010;9:68.
32. Horne HN, Lee PS, Murphy SK, Alonso MA, Olson JA, Jr., Marks JR: Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Mol Cancer Res 2009, 7(2):199–209.
33. Trifa F, Karray-Chouayekh S, Jmal E, Jmaa ZB, Khabir A, Sellami-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R. Loss of WIF-1 and Wnt5a expression is related to aggressiveness of sporadic breast cancer in Tunisian patients. Tumour Biol. 2013;34(3):1625–33.
34. Caldeira JR, Prando EC, Quevedo FC, Neto FA, Rainho CA, Rogatto SR. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer. 2006;6:48.
35. Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, Rossiello R, Liguoro G, Seripa D, Gravina C, et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res. 2004;10(16):5349–54.
36. Sebova K, Zmetakova I, Bella V, Kajo K, Stankovicova I, Kajabova V, Krivulcik T, Lasabova Z, Tomka M, Galbavy S, et al. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Biomark. 2011;10(1):13–26.
37. Park SY, Kwon HJ, Choi Y, Lee HE, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes. Mod Pathol. 2012;25(2):185–96.
38. Sun J, Xu X, Liu J, Liu H, Fu L, Gu L. Epigenetic regulation of retinoic acid receptor beta2 gene in the initiation of breast cancer. Med Oncol. 2011;28(4):1311–8.
39. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006;66(13):6512–20.
40. Subramaniam MM, Chan JY, Soong R, Ito K, Ito Y, Yeoh KG, Salto-Tellez M, Putti TC. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat. 2009;113(1):113–21.
41. Sharma G, Mirza S, Yang YH, Parshad R, Hazrah P, Datta Gupta S, Ralhan R. Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. Cell Oncol. 2009;31(6):487–500.
42. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
43. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. *Sci Transl Med*. 2011;3(75):75ra25.
44. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787–93.
45. Gargiulo P, Pensabene M, Milano M, Arpino G, Giuliano M, Forestieri V, Condello C, Lauria R, De Placido S. Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis. BMC Cancer. 2016;16:375.
46. Kwiatkowska E, Teresiak M, Filas V, Karczewska A, Breborowicz D, Mackiewicz A. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res. 2003;9(12):4452–9.
47. Bardowell SA, Parker J, Fan C, Crandell J, Perou CM, Swift-Scanlan T. Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns. Breast Cancer Res Treat. 2013;142(2):365–80.
48. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res. 2007;9(4):R57.
49. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jonsson G, Olsson H, Borg A, Ringner M. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 2010;12(3):R36.
50. Pang JMB, Dobrovic A, Fox SB. DNA methylation in ductal carcinoma in situ of the breast. Breast Cancer Res. 2013;15(3):206.
51. Deb S, Fox SB. Molecular profiling in colorectal cancer: current state of play and future directions. Colorectal Cancer. 2014;3(1):41–56.
52. Dobrovic A, Kristensen LS. DNA methylation, epimutations and cancer predisposition. Int J Biochem Cell Biol. 2009;41(1):34–9.
53. Nebert DW, Vasiliou V. Analysis of the glutathione S-transferase (GST) gene family. Hum Genomics. 2004;1(6):460–4.
54. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A. 1994;91(24):11733–7.
55. Millar DS, Ow KK, Paul CL, Russell PJ, Molloy PL, Clark SJ. Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene. 1999;18(6):1313–24.
56. Buyru N, Altinisik J, Ozdemir F, Demokan S, Dalay N. Methylation profiles in breast cancer. Cancer Investig. 2009;27(3):307–12.
57. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res. 1998;58(20):4515–8.
58. Re A, Aiello A, Nanni S, Grasselli A, Benvenuti V, Pantisano V, Strigari L, Colussi C, Ciccone S, Mazzetti AP, et al. Silencing of GSTP1, a prostate cancer prognostic gene, by the estrogen receptor-beta and endothelial nitric oxide synthase complex. Mol Endocrinol. 2011;25(12):2003–16.
59. Song JZ, Stirzaker C, Harrison J, Melki JR, Clark SJ. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene. 2002;21(7):1048–61.
60. Fridlich R, Annamalai D, Roy R, Bernheim G, Powell SN. BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication. DNA Repair (Amst). 2015;30:11–20.
61. Flanagan JM, Cocciardi S, Waddell N, Johnstone CN, Marsh A, Henderson S, Simpson P, da Silva L, kConFab I, Khanna K, et al. DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am J Hum Genet. 2010;86(3):420–33.
62. Conway K, Edmiston SN, May R, Kuan PF, Chu H, Bryant C, Tse CK, Swift-Scanlan T, Geradts J, Troester MA, et al. DNA methylation profiling in the Carolina breast cancer study defines cancer subclasses differing in clinicopathologic characteristics and survival. Breast Cancer Res. 2014;16(5):450.